The Analyst Verdict: AbbVie In The Eyes Of 5 Experts
The Analyst Verdict: AbbVie In The Eyes Of 5 Experts
分析师的判决：5位专家眼中的艾伯维
5 analysts have expressed a variety of opinions on AbbVie (NYSE:ABBV) over the past quarter, offering a diverse set of opinions from bullish to bearish.
在过去的一个季度中，有5位分析师对艾伯维（纽约证券交易所代码：ABBV）表达了各种观点，从看涨到看跌，提出了各种各样的观点。
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
下表汇总了他们最近的评级，阐明了过去30天内情绪的变化，并将其与前几个月进行了比较。
Insights from analysts' 12-month price targets are revealed, presenting an average target of $190.4, a high estimate of $200.00, and a low estimate of $180.00. Highlighting a 0.18% decrease, the current average has fallen from the previous average price target of $190.75.
分析师12个月目标股价的见解得以公布，平均目标股价为190.4美元，最高估计为200.00美元，低估值为180.00美元。当前的平均价格已从之前的190.75美元的平均目标股价下跌，这凸显了0.18％的跌幅。
Investigating Analyst Ratings: An Elaborate Study
调查分析师评级：一项详尽的研究
The perception of AbbVie by financial experts is...
金融专家对艾伯维...
登录免费看全文
登录/注册